The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction.
T cell anergy has been demonstrated to play a role in maintaining peripheral tolerance to self Ags as well as a means by which tumors can evade immune destruction. Although the precise pathways involved in anergy induction have yet to be elucidated, it has been linked to TCR engagement in the setting of cell cycle arrest. Indeed, rapamycin, which inhibits T cell proliferation in G(1), has the ability to promote tolerance even in the presence of costimulation. To better define the role of the cell cycle in regulating anergy induction, we used the novel cyclophilin-binding ligand, sanglifehrin A (SFA). We demonstrate that SFA can inhibit TCR-induced cytokine and chemokine production without preventing TCR-induced anergy. Our data also indicate that despite its ability to induce G(1) arrest, SFA does not induce anergy in the presence of costimulation. Furthermore, although SFA blocks proliferation to exogenous IL-2, it does not prevent IL-2-induced reversal of anergy. When we examined the phosphorylation of 4EBP-1, a downstream substrate of the mammalian target of rapamycin, we found that rapamycin, but not SFA, inhibited the mammalian target of rapamycin activity. Based on these data, we propose that the decision as to whether TCR engagement will lead to productive activation or tolerance is dictated by a rapamycin -inhibitable pathway, independent of the G(1)-->S phase cell cycle progression.
Allen
Amy
A
Division of Immunology and Hematopoeisis, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Zheng
Yan
Y
Gardner
Lawrence
L
Safford
Meredith
M
Horton
Maureen R
MR
Powell
Jonathan D
JD
D000818:Animals; D002455:Cell Division / Q000187:drug effects / Q000276:immunology; D002478:Cells, Cultured; D018925:Chemokines / Q000096:biosynthesis; D017635:Clonal Anergy / Q000187:drug effects / Q000276:immunology; D002999:Clone Cells; D021983:Cyclophilins / Q000378:metabolism*; D016207:Cytokines / Q000096:biosynthesis; D016193:G1 Phase / Q000187:drug effects* / Q000276:immunology*; D006131:Growth Inhibitors / Q000378:metabolism / Q000494:pharmacology*; D007108:Immune Tolerance / Q000187:drug effects*; D007166:Immunosuppressive Agents / Q000378:metabolism / Q000494:pharmacology*; D007783:Lactones / Q000378:metabolism / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases / Q000378:metabolism; D017260:Receptor-CD3 Complex, Antigen, T-Cell / Q000502:physiology; D020123:Sirolimus / Q000494:pharmacology; D013141:Spiro Compounds / Q000378:metabolism / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D058570:TOR Serine-Threonine Kinases
D018925:Chemokines; D016207:Cytokines; D006131:Growth Inhibitors; D007166:Immunosuppressive Agents; D007783:Lactones; D047428:Protein Kinase Inhibitors; D017260:Receptor-CD3 Complex, Antigen, T-Cell; D013141:Spiro Compounds; C121329:sanglifehrin A; D011494:Protein Kinases; C546843:mTOR protein, mouse; D058570:TOR Serine-Threonine Kinases; D021983:Cyclophilins; D020123:Sirolimus